Abstract
Association studies between Alpha-1-antichymotrypsin (ACT)-17(A>T) polymorphisms and Alzheimer’s disease (AD) susceptibility have shown conflicting results. In this investigation, we performed a meta-analysis to assess the purported associations. Subgroup analyses based on ethnicity (Caucasians, East-Asian and American mixed) were also performed including a total of 5,676 AD patients and 5,460 controls for ACT-17. Overall, allele contrast (A vs. T) of ACT -17 polymorphism produced significant results in the worldwide population [Pheterogeneity=0.01, random-effects (RE) odds ratio (OR) 1.12; 95% CI 1.04-1.21, P=0.003] and in the Caucasian population [Pheterogeneity=0.03, RE OR1.11 95% CI 1.01-1.24, P=0.04]. Meta-analyses of other genetic contrasts suggested that the A allele carriers are associated with increased susceptibility to AD in variant populations. No significant association was observed in the East-Asian subgroup analysis. In conclusion, ACT-17 variation presents a risk factor for AD in the worldwide population, especially in the Caucasian population.
Keywords: Abeta-peptide, Alpha-1-antichymotrypsin, Alzheimer’s disease, meta-analysis polymorphism, susceptibility
Current Alzheimer Research
Title:The Association of ACT -17 A/T Polymorphism with Alzheimer’s Disease: A Meta-Analysis
Volume: 10 Issue: 1
Author(s): Chao Dou, Jiyuan Zhang, Yang Sun, Xin Zhao, Qihan Wu, Chaoneng Ji, Shaohua Gu, Yi Xie and Yumin Mao
Affiliation:
Keywords: Abeta-peptide, Alpha-1-antichymotrypsin, Alzheimer’s disease, meta-analysis polymorphism, susceptibility
Abstract: Association studies between Alpha-1-antichymotrypsin (ACT)-17(A>T) polymorphisms and Alzheimer’s disease (AD) susceptibility have shown conflicting results. In this investigation, we performed a meta-analysis to assess the purported associations. Subgroup analyses based on ethnicity (Caucasians, East-Asian and American mixed) were also performed including a total of 5,676 AD patients and 5,460 controls for ACT-17. Overall, allele contrast (A vs. T) of ACT -17 polymorphism produced significant results in the worldwide population [Pheterogeneity=0.01, random-effects (RE) odds ratio (OR) 1.12; 95% CI 1.04-1.21, P=0.003] and in the Caucasian population [Pheterogeneity=0.03, RE OR1.11 95% CI 1.01-1.24, P=0.04]. Meta-analyses of other genetic contrasts suggested that the A allele carriers are associated with increased susceptibility to AD in variant populations. No significant association was observed in the East-Asian subgroup analysis. In conclusion, ACT-17 variation presents a risk factor for AD in the worldwide population, especially in the Caucasian population.
Export Options
About this article
Cite this article as:
Dou Chao, Zhang Jiyuan, Sun Yang, Zhao Xin, Wu Qihan, Ji Chaoneng, Gu Shaohua, Xie Yi and Mao Yumin, The Association of ACT -17 A/T Polymorphism with Alzheimer’s Disease: A Meta-Analysis, Current Alzheimer Research 2013; 10 (1) . https://dx.doi.org/10.2174/1567205011310010009
DOI https://dx.doi.org/10.2174/1567205011310010009 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microglial dependent protective effects of neuroactive steroids
CNS & Neurological Disorders - Drug Targets Current Acetylcholinesterase-Inhibitors: A Neuroinformatics Perspective
CNS & Neurological Disorders - Drug Targets Chronic Alcohol Abuse and HIV Disease Progression: Studies with the Non-Human Primate Model
Current HIV Research Non-Pharmacological Approaches to the Prevention and Treatment of Alzheimer’s Disease with Respect to the Rising Treatment Costs
Current Alzheimer Research Telomeres, Senescence and Longevity: The Role of Oxidative Stress and Antioxidants
Current Pharmacogenomics Non-Steroidal Anti-Inflammatory Drugs as Anti-Amyloidogenic Compounds
Current Pharmaceutical Design Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design Silybin and Silymarin - New and Emerging Applications in Medicine
Current Medicinal Chemistry Role of Nanomedicines in Delivery of Anti-Acetylcholinesterase Compounds to the Brain in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Complex Interactions between Phytochemicals. The Multi-Target Therapeutic Concept of Phytotherapy
Current Drug Targets Animal Models of Gastric Bleeding Induced by Dual Antiplatelet Therapy Using Aspirin and Clopidogrel - Prophylactic Effect of Antiulcer Drugs
Current Pharmaceutical Design Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design Efficient Synthesis and Discovery of Schiff Bases as Potent Cholinesterase Inhibitors
Medicinal Chemistry Modulation of Inflammation as a Way of Delaying Alzheimer's Disease Progression: The Diet's Role
Current Alzheimer Research Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research Recent Updates in the Alzheimer’s Disease Etiopathology and Possible Treatment Approaches: A Narrative Review of Current Clinical Trials
Current Molecular Pharmacology Implications of Prion Protein Biology
Current Neurovascular Research Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review
Current Molecular Pharmacology New Agents Promote Neuroprotection in Parkinson’s Disease Models
CNS & Neurological Disorders - Drug Targets Effects of Estrogen in the Brain: Is it a Neuroprotective Agent in Alzheimers Disease?
Current Aging Science